Zobrazeno 1 - 10
of 58
pro vyhledávání: '"M, Camean"'
Autor:
Flavio Oliveira, Leticia Diez-Quijada, Maria V. Turkina, João Morais, Aldo Barreiro Felpeto, Joana Azevedo, Angeles Jos, Ana M. Camean, Vitor Vasconcelos, José Carlos Martins, Alexandre Campos
Publikováno v:
Toxins, Vol 12, Iss 3, p 196 (2020)
Toxic cyanobacterial blooms are a major contaminant in inland aquatic ecosystems. Furthermore, toxic blooms are carried downstream by rivers and waterways to estuarine and coastal ecosystems. Concerning marine and estuarine animal species, very littl
Externí odkaz:
https://doaj.org/article/f5c1044ece144862b960b0bf4349aec3
Autor:
C. González-López, S. Sandoval Fernández del Castillo, M. Camean-Fernández, N. Navas-Iglesias, D. Fernández-Prieto, M.Á. Calleja-Hernández, L.J. Roca-Ruiz, A. Gutiérrez-Pizarraya, J.J. Ballester-Alfaro, María Núñez-Núñez, J. García-Donaire, M Murillo-Izquierdo, M.M. Villanova-López, A. Pérez-Pérez
Publikováno v:
Revista Española de Cirugía Ortopédica y Traumatología. 64:134-142
Resumen Objetivos Comparar la eficacia y seguridad de la infiltracion de plasma rico en plaquetas preparado respecto a acido hialuronico en pacientes con coxartrosis refractaria a tratamiento conservador. Asi como correlacionar el impacto clinico ent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a7a4de812783fb59a12f9d56f850f6c
https://doi.org/10.1016/j.recot.2019.09.008
https://doi.org/10.1016/j.recot.2019.09.008
Autor:
A. Gutiérrez-Pizarraya, J. García-Donaire, M Murillo-Izquierdo, N. Navas-Iglesias, A. Pérez-Pérez, S. Sandoval Fernández del Castillo, C. González-López, L.J. Roca-Ruiz, M.Á. Calleja-Hernández, D. Fernández-Prieto, J.J. Ballester-Alfaro, M.M. Villanova-López, María Núñez-Núñez, M. Camean-Fernández
Publikováno v:
Revista Española de Cirugía Ortopédica y Traumatología (English Edition). 64:134-142
Aims of the study To compare the efficiency and safety of platelet-rich plasma (PRP) injection versus hyaluronic acid (HA) in patients with hip osteoarthritis (OA) not responding to symptomatic treatment, and to correlate cellular composition of PRP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e648aa0d35c0b95db9bf85926f3bca7
https://doi.org/10.1016/j.recote.2020.02.003
https://doi.org/10.1016/j.recote.2020.02.003
Autor:
R Castillejo Garcia, A Martinez Suarez, C Castillo-Martin, L Rendón de Lope, J Cordero-Ramos, M Camean Fernandez
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Mucopolysaccharidosis VII (MPSVII), also known as Sly syndrome, is an ultra-rare disease characterised by deficiency of β-glucuronidase. Sly phenotypes vary from severe forms with hydrops fetalis and skeletal dysplasia, hep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfd7414c8832a002e3fa3cfae91fc971
https://doi.org/10.1136/ejhpharm-2021-eahpconf.85
https://doi.org/10.1136/ejhpharm-2021-eahpconf.85
Autor:
JM Borrero-Rubio, M Dominguez-Cantero, M Camean-Castillo, Silvia Fénix-Caballero, FJ Salmeron-Navas
Publikováno v:
Section 2: Selection, Procurement and Distribution.
Background and importance Regorafenib, ramucirumab and cabozantinib are used as secondline therapy in patients with hepatocarcinoma and alfa-fetoprotein value ≥400 ng/mL (HCC-AP ≥400). There are no direct comparisons among them. Aim and objective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b05e27bf5de352ca0e4e2ead430f9d9
https://doi.org/10.1136/ejhpharm-2020-eahpconf.25
https://doi.org/10.1136/ejhpharm-2020-eahpconf.25
Autor:
M M, Villanova-López, M, Núñez-Núñez, D, Fernández-Prieto, C, González-López, J, García-Donaire, A, Pérez-Pérez, S, Sandoval Fernández Del Castillo, M, Murillo-Izquierdo, M, Camean-Fernández, A, Gutiérrez-Pizarraya, N, Navas-Iglesias, L J, Roca-Ruiz, M Á, Calleja-Hernández, J J, Ballester-Alfaro
Publikováno v:
Revista espanola de cirugia ortopedica y traumatologia (English ed.). 64(2)
To compare efficacy and safety of a home-made platelet-rich plasma (PRP) solution versus hyaluronic acid in patients with hip osteoarthritis not responding to conservative treatment and to correlate cellular composition of PRP to clinical outcomes.Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7ae5674516ba9aaa93b6716e026c06ef
https://pubmed.ncbi.nlm.nih.gov/31902736
https://pubmed.ncbi.nlm.nih.gov/31902736
Autor:
FJ Salmeron-Navas, JM Borrero-Rubio, E Rios-Sanchez, Silvia Fénix-Caballero, Mdp Briceño-Casado, Gil-Sierra, M Camean-Castillo, EJ Alegre-Del Rey, J Diaz-Navarro, C Martinez-Diaz
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background After the approval of nivolumab some time ago it is necessary to analyse if the results of the randomised clinical trials are correlated with usual clinical practice. Purpose In this study we assessed median progression-free survival, over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3067474a44aa6303fa62e4b338e06fdf
https://doi.org/10.1136/ejhpharm-2019-eahpconf.256
https://doi.org/10.1136/ejhpharm-2019-eahpconf.256
Autor:
Mdp Briceño-Casado, Gil-Sierra, JM Borrero-Rubio, E Rios-Sanchez, Silvia Fénix-Caballero, C Martinez-Diaz, M Camean-Castillo, J Diaz-Navarro, EJ Alegre-Del Rey, FJ Salmeron-Navas
Publikováno v:
Section 2: Selection, Procurement and Distribution.
Background Due to the recent commercialisation of the presentations of Tenofovir Alafenamide (TAF) for HIV, there is a need to analyse the costs involved in its introduction into the public health system and its potential impact. Purpose The objectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6e7d0274706b9fa36b75aaf7e565b8c
https://doi.org/10.1136/ejhpharm-2019-eahpconf.45
https://doi.org/10.1136/ejhpharm-2019-eahpconf.45
Autor:
Gil-Sierra, JM Borrero-Rubio, E Rios-Sanchez, C Martinez-Diaz, EJ Alegre-Del Rey, C Palomo-Palomo, Mdp Briceño-Casado, M Camean-Castillo, J Diaz-Navarro, F Tellez-Perez, Silvia Fénix-Caballero
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background The European Medicines Agency authorised glecaprevir/pibrentasvir combination for treatment of hepatitis C virus (HCV) infection in July 2017. Treating hospital patients and the institutionalised population is essential in reducing transmi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5451cfb4feea1ad1a256c7fdc4cf3565
https://doi.org/10.1136/ejhpharm-2019-eahpconf.472
https://doi.org/10.1136/ejhpharm-2019-eahpconf.472
Autor:
M Camean-Castillo, Gil-Sierra, C Martinez-Diaz, Silvia Fénix-Caballero, Mdp Briceño Casado, EJ Alegre-Del Rey, JC Garciadeparedes-Esteban, J Diaz-Navarro, FJ Salmeron-Navas, JM Borrero-Rubio, E Rios-Sanchez
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Omalizumab is a recombinant humanised monoclonal antibody that suppresses allergen-mediated skin reactions through its block of the IgE receptor in basophils and mast cells. It is used in patients with chronic idiopathic urticaria who rema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b37f1fc668533705ef06304b801bfd16
https://doi.org/10.1136/ejhpharm-2019-eahpconf.330
https://doi.org/10.1136/ejhpharm-2019-eahpconf.330